The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I clinical trial of veliparib and temozolomide in children with recurrent central nervous system tumors: A Pediatric Brain Tumor Consortium report.
Jack M. Su
No relevant relationships to disclose
Patrick Andrew Thompson
No relevant relationships to disclose
Adekunle Adesina
No relevant relationships to disclose
Xiao-Nan Li
No relevant relationships to disclose
Lindsay Baker Kilburn
No relevant relationships to disclose
Arzu Onar-Thomas
No relevant relationships to disclose
Mehmet Kocak
No relevant relationships to disclose
Brenda Chyla
Stock Ownership - Abbott Laboratories
Evelyn Mary McKeegan
Stock Ownership - Abbott Laboratories
Katherine E. Warren
No relevant relationships to disclose
Stewart Goldman
No relevant relationships to disclose
Ian Pollack
No relevant relationships to disclose
Maryam Fouladi
No relevant relationships to disclose
Alice Chen
No relevant relationships to disclose
Malcolm A. Smith
No relevant relationships to disclose
Vincent L. Giranda
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
James M. Boyett
No relevant relationships to disclose
Susan Blaney
No relevant relationships to disclose
Larry E. Kun
No relevant relationships to disclose